LAS VEGAS—Correction of anemia with erythropoiesis-stimulated agents (ESAs) improves fatigue in dialysis patients compared with no treatment, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Oral iron is the optimal first treatment strategy for most iron-deficient, anemic chronic kidney disease (CKD) patients not yet on dialysis, based on a recent analysis presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Monthly requirements of erythropoiesis-stimulating agents (ESAs) to maintain target hemoglobin levels may be lower with larger doses of maintenance iron, according to data presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Switching anemic pre-dialysis chronic kidney disease (CKD) from darbepoetin to epoetin is associated with longer dosing intervals and lower drug costs, and hemoglobin levels are maintained in the recommended target range, according to a study presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Blood transfusions are common for non-dialysis chronic kidney disease (ND-CKD) patients with persistent anemia, according to a report presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Vitamin D repletion in patients with end-stage renal disease maintains hemoglobin (Hb) levels and results in decreased requirement of darbepoetin alfa, according to data presented at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Correction of iron deficiency does not significantly lower platelet counts in patients with chronic kidney disease (CKD), regardless of molecular weight or dose used, investigators reported at the National Kidney Foundation’s Spring Clinical Meetings.
LAS VEGAS—Darbepoetin alfa dosing intervals in pre-dialysis patients with chronic kidney disease (CKD) may be extended beyond the approved one- or two-week frequency, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
Please login or register first to view this content.
